银杏达莫联合依达拉奉治疗急性脑梗死72例疗效分析

目的观察银杏达莫联合依达拉奉治疗急性脑梗死的临床效果及安全性.方法将128例急性脑梗死患者分为治疗组与对照组,对照组患者给予常规方法治疗,治疗组在对照组基础上加用银杏达莫与依达拉奉联合给药治疗.结果完成既定疗程治疗时(入院15 d)除对照组NIHSS评分外,两组患者三方面指标数值均较入院时显著降低,但组间比较均以治疗组降低程度更为显著(P0.05);入院15 d内,治疗组与对照组的生存率分别为80.5%(58/72)和64.3%(36/56),经Log-rank检验,两组的生存率比较差异具有统计学意义(P0.05);半年随访,治疗组功能恢复良好者占到全组65.3%,显著高于对照组的39.3%,组间比较差异具有统计学意义(P0.05).结论银杏达莫联合依达拉奉治疗急性脑梗死临床疗效显著,建议将其作为当前临床治疗急性脑梗死疾病的重要备选方案.

Clinical Efficacy Analysis on 72 Cases of Acute Cerebral Infraction Treated by Ginkgo dipyridolum Combined with Edaravone

Objective To investigate the clinical efficacy and safety of Ginkgo dipyridolum combined with edaravone on the treatment of acute cerebral infarction ( ACI ) .Methods A total of 128 patients with acute cerebral infarction were divided into the treatment group(72 cases)and the control group(56 cases).The control group was given conventional therapy, and the treatment group was administered the combination of Ginkgo dipyridolum and edaravone on the basic therapy.Results When the course of treatment finished ( 15 days of admission) ,all the three indicators of the two groups decreased obviously except the NIHSS score of the control group.And the difference between the two groups was significant(P<0.05).Within 15 days of admission,the survival rates of treatment group and control group were 80.5%(58/72) and 64.3%(36/56),respectively.According to log-rank test,the difference was statistically significant(P<0.05).The half-year follow-up showed that,the functional recovery rate of the treatment group(65.3%) was significantly higher than the control group (39.3%)(P<0.05).Conclusion The clinical effect of Ginkgo dipyridolum combined with edaravone on the treatment of ACI was remarkable.Therefore,this therapeutic regimen could be an important alternative to treat ACI.